Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $66 to $64.
Read original at benzingaStocks · News reference
Pelthos Therapeutics Q2 EPS $(6.62) Misses $(3.05) Estimate, Sales $15.603M Beat $15.273M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.62) per share which missed the analyst consensus estimate of $(3.05) by 117.05 percent. This is a 23.05 percent decrease over losses of $(5.38) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 11:12 AM
- Checked
- Aug 13, 2026, 11:12 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Pelthos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
Pelthos Therapeutics (AMEX:PTHS) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and
Read original at benzinga8-K filing — Pelthos Therapeutics Inc. (PTHS)
Filed: 2026-08-13 AccNo: 0001919246-26-000112 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar